New antibiotic shows promise for treating MRSA pneumonia Date: September 11, 2013 Source: Henry Ford Health System Summary: A drug approved just two years ago for treating bacterial infections may ...

Objective: To discuss current and potential treatment options for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA). Data Sources: A MEDLINE search (1966-January 2007 ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs ...

Viromed Medical AG: Revolutionary cold plasma therapy for the treatment of ventilator-associated pneumonia (VAP) shows 100% efficacy in an in vitro study with MRSA and human lung cells (alveoli) Study ...

Basilea Pharmaceutica announces commercial availability of antibiotic Zevtera in United States: Allschwil, Switzerland Wednesday, May 21, 2025, 11:00 Hrs [IST] Basilea Pharmaceuti ...

organisms such as methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas and Acinetobacter have been debated. We therefore compared patients with HCAP, hospital-acquired pneumonia (HAP ...

The penicillin market thrives on its enduring efficacy and affordability in treating bacterial infections, particularly in ...

This germy spot will make you need the bad kind of R&R—rest and recuperation. Here's what you need to know before your next ...

Staphylococcus aureus bacteremia (SAB) is a serious bloodstream infection associated with significant morbidity and mortality.(3) Complications ...

Delmarva hospitals' safety grades improved in spring 2025, with five A's, one B, and three C's. Explore what these scores say ...

Antimicrobial-resistant (AMR) “superbugs” contribute to more than 4.5 million deaths globally per year and threaten to make ...

Sometimes when patients are admitted to hospitals, they catch infections known as "hospital-acquired" or "healthcare-associated" infections.